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BACKGROUND AND PURPOSE 
(-)-Englerin A (EA) is a potent cytotoxic agent against renal cell carcinoma cells. It achieves its 
effects by activation of TRPC4/TRPC1 heteromeric channels. It is also an agonist at channels 
formed by the related protein, TRPC5. Here we sought an EA analogue which might enable better 
understanding of these EA effects. 
 
EXPERIMENTAL APPROACH 
Renal cell carcinoma A498 cells and HEK 293 cells overexpressing TRPC4 or TRPC5 were 
studied by intracellular Ca2+ measurement or whole-cell patch-clamp. The EA analogue A54 was 
generated by total synthesis.  
 
KEY RESULTS 
A54 had weak or no agonist activity at endogenous TRPC4/TRPC1 channels in A498 cells or 
TRPC4 or TRPC5 homomeric channels overexpressed in HEK 293 cells. A54 strongly inhibited 
EA-mediated activation of TRPC4/TRPC1 or TRPC5 and weakly inhibited activation of TRPC4. 
Studies of TRPC5 showed that A54 right-shifted the EA concentration-response curve without 
changing its slope, consistent with competitive antagonism. In contrast, TRPC5 activated by Gd3+ 
and TRPC4 activated by sphingosine-1-phosphate were not inhibited but potentiated by A54. A54 
did not activate TRPC3 channels or affect activation of these channels by the agonist 1-oleoyl-2-
acetylglycerol. 
 
CONCLUSIONS AND IMPLICATIONS 
The data suggest identification of a tool compound which could be useful for characterizing 
endogenous TRPC1/4/5 channels and understanding EA binding sites and their physiological 
relevance. 
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Abbreviations 
TRPC, Transient Receptor Potential Canonical; EA, (-)-Englerin A; A54, Analogue 54; HEK 293 
cells; human embryonic kidney 293 cells; A498 cells, human renal cell carcinoma cell line 498; 
Gd3+, gadolinium ion.   
 
Introduction 
 
(-)-Englerin A is a natural product from Phyllanthus engleri, a South East African plant (Wu et 
al., 2017). It was found to have potent cytotoxic effects against some types of cancer cell cultured 
from kidney, breast, bone, brain, lung, hematopoietic, prostate and other cancers (Akbulut et al., 
2015, Caropreso et al., 2016, Carson et al., 2015, Ratnayake et al., 2009, Sourbier et al., 2013). 
Subsequent studies reported in vivo efficacy against xenograft tumours generated in mice using 
786-O and PC3 cancer cell lines, suggesting potential for a novel therapeutic strategy (Sourbier et 
al., 2013). Chemistry studies led to the development of efficient synthesis routes for (-)-Englerin 
A and derivatives of it and gave initial insights into structure-activity relationships (Radtke et al., 
2011, Willot et al., 2009, Wu et al., 2017).  
 
The Transient Receptor Potential Canonical (TRPC) proteins are a subfamily of the TRP super 
family and assemble as homo- and hetero-tetramers to form Ca2+-permeable non-selective cationic 
channels (Abramowitz and Birnbaumer, 2009, Beech, 2013, Damann et al., 2008, Gaunt et al., 
2016, Moran et al., 2011, Rubaiy, 2017). They appear to function in two clusters, 
TRPC1/TRPC4/TRPC5 (TRPC1/4/5) and TRPC3/TRPC6/TRPC7, which are distinguishable 
pharmacologically (Akbulut et al., 2015, Bon and Beech, 2013, Maier et al., 2015, Miller et al., 
2011, Rubaiy et al., 2017b, Washburn et al., 2013, Rubaiy et al., 2017a). 
 
TRPC1/4/5 channels are potently and strongly activated by EA whereas TRPC3 and TRPC6 
channels are unaffected (Akbulut et al., 2015, Carson et al., 2015, Ludlow et al., 2017, Rubaiy et 
al., 2017b). EA-evoked cytotoxicity is TRPC4 dependent in A498 renal cell carcinoma and other 
cancer cell lines (Carson et al., 2015, Ludlow et al., 2017). TRPC5 is poorly expressed in many 
cancer cell lines but may be relevant in some cancer cell types (Carson et al., 2015, Ma et al., 
2012). The role of TRPC1 is not completely understood but its involvement in the A498 cell and 
Hs578T triple-negative breast cancer cell death evoked by EA and relevance to the control of Na+ 
versus Ca2+ permeability in these cells has been suggested (Ludlow et al., 2017). Therefore, ion 
channels comprising TRPC1/4/5 proteins are an important target of EA and might be a platform 
for developing novel anti-cancer agents (Gaunt et al., 2016, Wu et al., 2017). However, obstacles 
to a therapeutic strategy include metabolic instability and in vivo toxicity (Carson et al., 2015). A 
potential route to overcoming such obstacles is a better understanding of the structure-activity 
relationships of EA at TRPC1/4/5 channels. To this end, we have sought chemical elaboration of 
EA. Here we report on a novel EA analogue and suggest that it is a competitive antagonist with 
partial agonist capability. 
 
Methods 
 
Cell Culture  
Human embryonic kidney 293 cells (HEK-293 cells) stably expressing human TRPC5 or human 
TRPC4E (tetracycline inducible promoter) were cultured at 37 °C in a humidified atmosphere 
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containing 5% CO2 / 95% air. The HEK-293 were from Invitrogen (T-5([ 7HWUDF\FOLQH-
Regulated Expression cell line stably expressing tetracycline (Tet) repressor). To induce the 
channel expression, WHWUDF\FOLQHȝJP/-1) was added to the cells at least 24 hours before the 
H[SHULPHQW'XOEHFFR¶VPRGLILHG(DJOHPHGLXm-F12 GlutaMAX (Invitrogen, Paisley, UK) was 
used with supplementation of 10% fetal bovine serum (FBS) and 5% with penicillin-streptomycin 
(10,000 units and 10 mg streptomycin per mL in 0.9% NaCl, sigma). The cell culture medium was 
supplemented with the sHOHFWLRQDQWLELRWLFVEODVWLFLGLQȝJP/-1DQGSKOHRP\FLQȝJP/-
1, Zeocin) (Invitrogen). The culture medium was changed every 3-4 days until the cells were 70 - 
80% confluent. The cells were used at passages 5 to 20 and the same seeding conditions were 
maintained between experiments. A-498 renal cell carcinoma cells were from DSMZ (The 
Leibniz-Institute±Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany). 
These cells were originally established from the kidney carcinoma of a 52-year-old man in 1973. 
A498 were cultured in Minimum Essential Medium (MEM) Eagle medium with EBSS, L-
glutamine, 2.2 g L-1 NaHCO3 (PAN-biotech, Germany) supplemented with 5% sodium pyruvate. 
 
Intracellular Calcium Measurement 
HEK-293 or A498 cells were plated at 90% confluence in microplates (96-well plates) and 
incubated overnight at 37 °C, 5% CO2. For HEK-293 cells clear-bottomed poly-D-lysine-coated 
black plates (Corning Life Sciences, Lowell, MA) and for A498 cells, clear-bottomed Nunc plates 
(Thermo Scientific) were used. The cells were illuminated with alternating 340/380 nm excitation 
light for fura-2 fluorescence measurements. Fluorescence emission was measured at 510 nm. In 
more detail, the cells were incubated for 1 hr with fura-2-AM (2 µM) in Standard Bath Solution 
(SBS) at 37 ºC in the presence of 0.01% pluronic acid. The fura-2 fluorescence was recorded using 
a 96-well fluorescence plate reader and the excitation wavelengths of 340 and 380 nm (FlexStation 
II384, Molecular Devices, Sunnyvale, CA, USA). Ca2+ was indicated by the ratio of the 
fluorescence (F) emission intensities for the two excitation wavelengths. Measurements were made 
at room temperature (21 ± 3 ºC). 
 
Patch-clamp recording 
Conventional whole-cell configuration was performed under voltage clamp at room temperature 
using 3±6-megaohm patch pipettes fabricated from borosilicate glass capillaries with an outside 
diameter of 1 mm and an inside diameter of 0.58 mm (Harvard Apparatus). The currents were 
recorded using an Axopatch 200B amplifier, digitized by a Digidata 1440, and recorded to a 
computer using pCLAMP10 (Molecular Devices). The data were filtered at 1 kHz and analyzed 
off-line using Clampfit software (version 10.2, Molecular Devices) and Origin software version 
9.1 (OriginLab, Northampton, MA). The bath solution was SBS, and the pipette solution 
(intracellular solution) contained 145 mM CsCl, 2 mM MgCl2, 10 mM Hepes, 1 mM EGTA (free 
acid), 5 mM ATP (sodium salt), and 0.1 mM GTP (sodium salt), titrated to pH 7.2 with CsOH. 
Cells were plated 24 h previously on glass coverslips at a low density of 20±30% and induced with 
tetracycline (1 µg/ml). 
 
Chemical Synthesis 
7KHV\QWKHVLVRIHWKHUGHULYDWLYH$LQ)LJ6FRPPHQFHGIURPDOFRKROZKLFKLVUHDGLO\
DFFHVVLEOH LQ WZR VWHSV 6XSSRUWLQJ LQIRUPDWLRQ IURPDNH\ LQWHUPHGLDWHRISUHYLRXV HQJOHULQ
V\QWKHVHV5DGWNHHWDO:LOORWHWDO$QLULGLXPFDWDO\]HGHWKHULILFDWLRQRIDOFRKRO
JDYHYLQ\OHWKHULQ\LHOG2NLPRWRHWDO6XEVHTXHQWK\GURERUDWLRQDIIRUGHGWKH
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JO\FROHWKHULQ\LHOG+RYH\GDHWDO7KHSULPDU\K\GUR[\OZDVSURWHFWHGDVVLO\O
HWKHU  LQ  \LHOG IROORZHG E\ K\GURJHQRO\WLF FOHDYDJH RI EHQ]\O HWKHU WR JLYH DOFRKRO 
)LQDOO\<DPDJXFKL HVWHULILFDWLRQ ZLWK FLQQDPLF DFLG DIIRUGHG HVWHU   \LHOG ZKLFK ZDV
WUHDWHGZLWKWHWUD1EXW\ODPPRQLXPIOXRULGH7%$)WRJLYHWKHWDUJHWPROHFXOHLQ\LHOG
,QDQDJDHWDO.DZDQDPLHWDO 
 
Reagents 
(-)-EA and A54 were stored in aliquots at -80°C. A54 stock and working solutions were prepared 
similarly to those of (-)-EA, as previously described (Akbulut et al., 2015). The (-)-EA analogues 
were diluted to a final concentration using the standard bath solution (SBS) containing 0.1% 
DMSO and 0.01% pluronic acid. The SBS, which was the experimental buffer, contained (mM): 
NaCl 135, KCl 5, MgCl2 1.2, CaCl2 1.5, glucose 8 and Hepes 10 (pH titrated to 7.4 using NaOH).  
 
Data Analysis 
All data are presented as means ± standard error of the mean (SEM) and P < 0.05 considered 
statistically significant after Two-Sample Test (t-test) for comparisons of two independent groups 
or ANOVA (One-Way, and post test Bonferroni) for multiple groups (post hoc test was only 
applied when ANOVA gave P < 0.05). Origin 9.1 software was used to analyse the results. In Ca2+ 
studies, the half maximal inhibitory concentration (IC50) was obtained by normalizing to the 
maximal response of (-)-Englerin A and the curves were fitted in Origin 9.1 software using y = 
START + (END - START) * xn / (kn + xn), where y is the Ca2+ concentration (reflected by fura-2 
ratio), x the concentration of the compound, k the IC50 or EC50, and n the number of binding site 
per target molecule. The rate of rise of the Ca2+ signal in response to Gd3+ was fitted in Origin 9.1 
using y = A1*exp(-x/t1) + y0, where y is Ca2+, x time, A1 the maximum response, y0 the Ca2+ at 
the time of Gd3+ application, and t1 the time constant. The data in all experiments are represented 
as n/N, where n indicates independent experiments and N indicates replicates in columns of the 
96-well plate. Statistical significance is indicated by * (P < 0.05). 
 
Results 
 
Structures of (-)-Englerin A (EA), Englerin B (EB) and Analogue 54 (A54) 
 
EA and its inactive metabolite EB (Fig. 1A, B) were used to guide the generation of analogues 
which might be active at endogenous TRPC4/5-containing channels. In this article we show the 
structure and data for only one of these analogues, A54 (Fig. 1C). Synthesis routes and chemical 
validation are provided (Supplementary Fig. S1).  
 
A54 lacks agonist activity but inhibits EA-evoked Ca2+entry in A498 cells 
 
To test the functionality of EA and its analogues we first used intracellular Ca2+ measurement in 
the A498 cells which express endogenous EA-responsive TRPC4/TRPC1 heteromeric channels 
(Akbulut et al., 2015, Ludlow et al., 2017). Initially, a single concentration of each compound was 
tested. As expected, EA was effective and EB ineffective (Fig. 2A, B). Like EB, A54 failed to 
evoke a Ca2+ signal and therefore appeared to be inactive (Fig. 2A, B). Nevertheless, we also tested 
if A54 could affect the response to EA. A498 cells were pre-incubated with 1 µM A54 for 30 min 
and then 100 nM EA was tested in the continuous presence of A54 (Fig. 2C). Strikingly, A54 
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abolished the EA response (Fig. 2C). In contrast, EB failed to affect the EA response (Fig. 2C). 
We next constructed a concentration-response curve for A54 against the EA response, pre-
incubating A498 cells with A54 at a range of concentrations (1-1000 nM) for 30 min and then 
testing EA (Fig. 2D). A54 was a potent inhibitor of the EA response, causing 50% inhibition at 62 
nM (Fig. 2D, E). The data suggest that A54, unlike EB, is an antagonist of EA. 
 
 
EA-dependent inhibition of TRPC5 channels by A54 
 
To gain insight into the mechanism of inhibition by A54 we switched to studying HEK 293 cells 
which contain tetracycline-inducible expression of human TRPC5, generating TRPC5 homomeric 
channels. These cells exhibit not only TRPC5 activity evoked by EA but also robust, albeit smaller, 
TRPC5 activity evoked by gadolinium ions (Gd3+) (Akbulut et al., 2015, Ludlow et al., 2017, 
Naylor et al., 2016) (Fig. 3A). We could, therefore, test A54 against two different modes of channel 
activity to determine if the effect of A54 had specificity for the EA response. EA evoked a large 
Ca2+ response in the TRPC5-expressing cells and, as expected, this effect was abolished by A54 
(Fig. 3A, B). A54 did not however inhibit the Gd3+ response, but enhanced its amplitude and rate 
of onset (Fig. 3A, C, D).  
To further investigate the dual effect of A54 we used whole-cell patch-clamp. EA activated 
TRPC5-mediated current as expected (Fig. 4A, B). Addition of A54 in the continuous presence of 
EA caused striking inhibition of the EA-evoked current (Fig. 4A-D) and this effect was reversible 
on wash-out of A54 (Fig. 4A, B). The channels could also be activated by Gd3+ but in this case 
A54 further enhanced the current (Fig. 5A-D). The data suggest that the inhibitory effect of A54 
is EA-dependent and that, in the absence of EA, A54 has a sharply contrasting positive effect on 
the Gd3+ response.  
 
A54 behaves like a competitive antagonist of EA at TRPC5 channels 
 
Because the inhibitory effect of A54 is EA-dependent we considered whether it might bind part of 
the same site as EA and thus compete with EA. To test this hypothesis, we constructed 
concentration-response curves for EA in the absence of A54 and in the presence of two different 
concentrations of A54 (10 and 50 nM) (Fig. 6A-C). The inhibition by A54 was surmountable and 
increasing concentrations of A54 caused parallel rightward shifts in the EA concentration-response 
curve (Fig. 6D). Schild analysis revealed a slope close to unity (Fig. 6E). EA responses reached 
steady-state for most concentrations of EA but the slowness of the response to low concentrations 
of EA meant that the responses fell short of steady-state in some instances. We accepted this 
weakness because of concern about the health of cells when long exposures to EA were used. The 
data suggest that A54 is a competitive antagonist of EA at TRPC5 channels. 
 
A54 is a weak antagonist of EA at TRPC4 channels 
 
We next investigated the effect of A54 on TRPC4 homomeric channels overexpressed in HEK 293 
cells. Unexpectedly, A54 was only a mild antagonist of EA at TRPC4 channels (Fig. 7A, B) and 
furthermore A54 lacked agonist activity on TRPC4 channels (Fig. 7C). The data suggest that the 
EA binding site associated with TRPC4 channels does not bind A54 efficiently or that A54 binds 
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tightly but does not compete effectively with EA. These findings contrast with TRPC5 channels 
and native TRPC4/TRPC1 channels. 
 
A54 strongly potentiates S1P-evoked TRPC4 activity 
 
To further investigate the relationship between A54 and TRPC4 channels we used a physiological 
agonist, S1P, which activates TRPC4 channels via G protein signaling. Strikingly, A54 markedly 
potentiated S1P-evoked Ca2+ entry through TRPC4 channels (Fig. 7C, D). The data suggest that 
A54 is an enhancer of TRPC4 channel activity evoked by S1P.  
 
A54 has no effect on TRPC3 channels 
 
EA appears to be selective for TRPC1/4/5 channels, lacking effect on 13 other ion channels 
investigated including TRPC3, a member of the TRPC3/TRPC6/TRPC7 subfamily of TRPC 
channels (Akbulut et al., 2015). Here we investigated if there was effect of A54 on TRPC3 
homomeric channels overexpressed in HEK 293 cells. A54 (1 PM) did not activate TRPC3 or 
inhibit or potentiate TRPC3-mediated Ca2+ entry activated by the TRPC3 agonist 1-oleoyl-2-
acetylglycerol (OAG) (Fig. 8A, B). The data suggest that A54 has no effect on TRPC3 channels. 
 
Discussion and conclusions 
 
The study reveals how subtle chemical elaboration of EA can lead to a compound (A54) which is 
a potent antagonist of EA at TRPC5 homomeric channels and endogenous TRPC4/TRPC1-
containing channels, yet not a general blocker of the channels. The antagonism had characteristics 
of surmountable competitive antagonism at TRPC5 channels, suggesting that A54 interacts at the 
same site as EA but is not able to trigger channel opening. Strikingly, however, A54 was a strong 
enhancer of TRPC5 channel activity which had already been induced by Gd3+ and TRPC4 channel 
activity induced by S1P. A54 is therefore capable of antagonist and enhancer (facilitating) activity; 
i.e. it is not a pure antagonist but retains some agonist-like (enhancer) capability in the presence of 
a co-factor (Gd3+ or S1P). 
 
The existence and location of a binding site for EA is unknown but its ability to robustly activate 
TRPC4 channels in excised membrane patches even in the complete absence of exogenous co-
factors is suggestive of an agonist binding site on the channel protein itself (Akbulut et al., 2015). 
This site is either on the extracellular surface of the channels or only accessible via the outer leaflet 
of the bilayer because EA only activates the channels when applied to the outer and not inner 
surface of the membrane (Akbulut et al., 2015). By implication, the A54 site would also be on the 
channel itself. Direct proof is however lacking. 
 
The action of EA on TRPC1/4/5 channels is remarkable ± it is much stronger and more robust as 
an agonist than other known activators of the channels. Therefore, there would seem not only to 
be an EA binding site on the channels but also the very efficient coupling of this binding site to 
channel activation. Such a site may simply exist by chance and serve no physiological purpose, 
but it might alternatively serve a purpose which is not yet recognised. In this latter regard, it will 
be interesting to test competitive antagonists of EA (e.g. A54) in physiological studies. 
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As TRPC4 and TRPC5 proteins share 65% amino acid sequence, we were expecting A54 to block 
the TRPC4 Ca2+ entry evoked by EA. Surprisingly, however, 1 µM A54 had only a modest 
inhibitory effect (Fig. 7) compared with full inhibition at TRPC5 channels (Figs. 2 and 3). 
Moreover, A54 had an enhancing effect in the presence of the physiological agonist S1P, 
increasing the Ca2+ entry more than 3-fold (Fig. 7). The effect was similar to the enhancing effect 
of A54 at TRPC5 channels in the presence of Gd3+ (Figs. 3 and 5). Such effects might be explained 
by a conformational change in the channels (induced by S1P or Gd3+) which allows A54 to access 
an efficacy (agonist) site. Therefore, the EA and A54 data could be explained by the existence of 
two binding sites which are in close physical proximity: Site 1 allowing binding without efficacy, 
and Site 2 allowing binding and efficacy. In this model, EA would bind Sites 1 and 2 (and therefore 
have direct agonist effect), while A54 would bind only Site 1 in the absence of a co-factor (and 
therefore antagonise EA) but also Site 2 in the presence of the co-factor (and therefore have an 
enhancing effect). 
In conclusion, the study has revealed a new tool compound for EA and TRPC1/4/5 channel 
research and, to the best of our knowledge, the first known competitive antagonist of EA.  This 
was achieved by minimal structural modification to EA. It is not a perfect antagonist because it 
has enhancer capability in the presence of a co-factor (Gd3+ at TRPC5 channels and S1P at TRPC4 
channels) but it shows impressive capability as a surmountable competitive antagonist when used 
in isolation in the low to middle nanomolar concentration range. The compound should facilitate 
studies aimed at better understanding TRPC1/4/5 channel activation, TRPC1/4/5 channel binding 
sites, and the physiological relevance of the action of EA. Because of the in vivo toxicity of EA 
(Carson et al, 2015), such a competitive antagonist might also have use as an antidote to EA 
poisoning. 
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Figure 1. Structures of (-)-Englerin A (EA), Englerin B (EB) and Analogue A54. 
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Figure 2. Activity of (-)-Englerin A (EA), Englerin B (EB) and analogue 54 (A54) in A498 
cells. (A) Representative Ca2+ measurement data from a single 96-well plate showing the EA-
evoked Ca2+ entry (black circles) and lack of effect of EB (red circle) or A54 (green triangle) in 
A498 cells. (B) Summary data for experiments of the same type (A) plotted as a percentage of the 
maximum EA response and expressed as percentages (n/N = 7/21, one-way ANOVA and post-test 
Bonferroni). (C) Representative traces showing 1 µM of A54 (green) was sufficient to inhibit 
activation by EA (100 nM) whereas 1 µM EB lacked effect (red). (D) Example concentration-
dependent inhibition traces of 100 nM EA responses by A54 at increasing concentrations (numbers 
1-1000 indicate concentrations in nM). (E) Concentration-response data for inhibition of EA 
responses by A54 fitted with the Hill equation (IC50 = 62 ± 17 nM, slope = 0.8 ± 0.01) (n/N = 5/15, 
mean ± SEM). 
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Figure 3. A54 inhibits EA but not Gd3+-evoked TRPC5 channel activity. Intracellular Ca2+ 
responses in HEK-TRPC5 cells to EA (100 nM, black) and Gd3+ (30 µM, red) in the absence and 
presence of 1 µM A54 (A). (B) For EA experiments of the type illustrated in (A), mean ± standard 
error of the mean data normalized to the vehicle control for A54 (n/N = 8/32). (C) For Gd3+ 
experiments of the type illustrated in (A), mean ± standard error of the mean data normalized to 
the vehicle control for A54 (n/N = 8/32). The time-point at which the amplitude of the Gd3+ 
response was measurement was from 150 to 200 seconds. (D) Activation time-course of Gd3+ 
responses in the absence and presence of A54. The curves were fitted exponential functions with 
time constants of 780 ± 7.6 s (Gd3+ -A54) and 18.1 ± 3.9 s (Gd3+ +A54) (n/N = 8/32). 
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Figure 4. A54 inhibits EA-evoked current in TRPC5 channels. (A) Example whole cell patch 
clamp data from a TRPC5-expressing HEK 293 cell showing current sampled at -100 and +100 
mV during ramp changes in voltages (all agents were bath-applied). 10 nM EA and 1 µM A54 
were used. Vehicle (Veh.) was DMSO. Wash indicates wash-out of EA and A54. (B) 
Representative current-voltage relationship (IVs) from experiments of the type illustrated in (A). 
(C, D) Mean percentage inhibition responses to A54 as illustrated in (A) for +100 mV (C) and -
100 mV (D) (n = 5 independent recordings). 
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Figure 5. A54 enhances Gd3+-evoked current in TRPC5 channels. (A) Example whole cell 
patch clamp data from a TRPC5-expressing HEK 293 cell showing current sampled at -100 and 
+100 mV during ramp changes in voltages (all agents were bath-applied). 3 PM Gd3+ and 1 µM 
A54 were used. Wash indicates wash-out of Gd3+ and A54. (B) Representative current-voltage 
relationship (IVs) from experiments of the type illustrated in (A). (C, D) Mean percentage 
enhancing responses to A54 as illustrated in (A) for +100 mV (C) and -100 mV (D) (n = 5 
independent recordings). 
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Figure 6. A54 causes parallel rightward shifts of the EA concentration-response curve. (A-
C) Example data from HEK-TRPC5 cells showing concentration-dependence of EA responses in 
the presence of 0 nM (A), 10 nM (B) and 50 nM (C) A54. (D) Mean ± SEM concentration-response 
data for experiments of the type illustrated in (A-C) (n/N = 6/24 for 0 and 50 nM and n/N = 5/16 
for 10 nM). EA EC50s were 1.7 nM (0 nM A54), 4.2 nM (10 nM A54) and 14.3 nM (50 nM A54). 
EA slope values were 1.4 (0 nM A54), 1.3 (10 nM A54), and 1.3 (50 nM A54). (E) Schild plot 
regression analysis with a slope near 1 (0.9) indicating that A54 is a competitive antagonist (DR 
in Y axis indicates the dose ratio). 
  
    
16 
 
 
 
 
Figure 7. A54 is a striking enhancer of S1P-evoked TRPC4 channel activity. (A) Intracellular 
Ca2+ responses in HEK-TRPC4 cells to EA (100 nM, black) in the absence and presence (green) 
of 1 µM A54. (B) Mean ± standard error of the mean data normalized to the vehicle control for 
A54 of the type illustrated in (A) (n/N = 5/15 for all data). (C) Intracellular Ca2+ responses in HEK-
TRPC4 cells to A54 (1 µM, orange) and S1P (5 µM, red) in the absence and presence (blue) of 1 
µM A54. (D) Mean ± standard error of the S1P mean data normalized to the vehicle control for 
A54 of the type illustrated in (C), (n/N = 5/15 for all data). 
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Figure 8. Lack of effect of A54 on TRPC3 channel activity. (A) Intracellular Ca2+ responses to 
A54 (1 µM, orange) and 1-oleoyl-2-acetyl-snglycerol (OAG, 50 µM, black) in the absence and 
presence (red) of 1 µM A54 in HEK 293 Tet+ cell lines stably expressing human TRPC3 (n/N = 
6/18). (B) Mean ± standard error of the mean data normalized to the vehicle control for A54 of the 
type illustrated in (A) (n/N = 6/18). 
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Supplementary Figure S1. Chemical synthesis and validation of analogue A54 (1). 
Supporting Information 
 
 
Identification of an (-)-Englerin A analogue which antagonizes (-)-Englerin 
A at TRPC1/4/5 channels 
 
General Information 
1H and 13C NMR spectral data were recorded at 400/500/700 MHz (1H) and 101/126/176 MHz (13C) on 
a JEOL ECX400 spectrometer/ JEOL ECP500 spectrometer/ BRUKER AVANCE500 spectrometer/ 
Bruker AVANCE700 spectrometer. The chemical shifts were referenced to the corresponding residual 
solvent signal (CDCl3: įH = 7.26 ppm, įC = 77.16 ppm). IR spectra were measured on a Jasco FT/IR-
4100 equipped with an ATR unit. All IR spectra were measured with neat substances. High resolution 
ESI-TOF mass spectra were measured on an Agilent 6210-System. Optical rotation values were 
measured on a Jasco P-2000 polarimeter. Products were purified by flash chromatography on silica gel 
300-400 mesh (Macherey & Nagel). Unless otherwise indicated, all reagents were purchased from 
commercial distributors and used without further purification. Dry THF, dry PhMe and dry CH2Cl2 were 
purified over a MBRAUN MB SPS-800 system from HPLC grade solvents. 
 
(((1R,3aR,4S,5R,7R,8S,8aR)-8-(benzyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-epoxyazulen-
5-yl)oxy)(tert-butyl)dimethylsilane (B) 
 
An oven-dried 10 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with alcohol A (100 mg, 271 ȝmol, 1.00 equiv) and dry THF (2.7 mL) under an argon 
atmosphere. The solution was cooled to 0 °C and KHMDS (1M in THF) (1.40 mL, 1.36 mmol, 5.00 
equiv) was added dropwise. Then benzyl bromide (ȝ/PPROHTXLY) was added and the 
reaction was stirred for additional 20 min. The reaction was quenched by adding 1M HCl solution 
(10 mL) and extracted with Et2O (4 × 2 mL). The combined organic phases were dried over sodium 
sulfate and the solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (pentane±Et2O, 50:1) to give the ether B (112 mg, 244 ȝPRODVD
clear oil. 
>Į@D20 íc 1.00, CHCl3), 1H NMR (700 MHz, CDCl3į 7.37 ± 7.27 (m, 4H), 7.28 ± 7.25 (m, 1H), 
4.70 (d, J = 10.9 Hz, 1H), 4.59 (d, J = 11.0 Hz, 1H), 3.92 (dd, J = 7.5, 2.6 Hz, 1H), 3.47 (d, J = 9.7 Hz, 
1H), 2.40 (ddd, J = 13.8, 9.1, 6.9 Hz, 2H), 2.07 (hept, J = 6.9 Hz, 1H), 1.96 (dddd, J = 13.7, 11.5, 8.1, 
2.8 Hz, 1H), 1.72 ± 1.59 (m, 3H), 1.39 (ddd, J = 13.2, 9.8, 6.4 Hz, 1H), 1.32 ± 1.21 (m, 1H), 1.17 (s, 
3H), 1.05 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 7.0 Hz, 3H), 1.04 ± 1.01 (m, 1H), 0.96 (d, J = 7.1 Hz, 3H), 
0.89 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H) ppm. 13C NMR (176 MHz, CDCl3į 139.3, 128.4 (2C), 127.5, 
127.4 (2C), 85.8, 85.4, 78.2, 73.0, 72.6, 48.1, 47.6, 42.8, 32.6, 32.0, 31.4, 25.9 (3C), 24.6, 19.9, 18.5, 
18.3, 17.7, 17.6, -4.5, -4.9 ppm. IR (neat): 2955, 2929, 2857, 1471, 1461, 1380, 1253, 1086, 1066, 1022, 
1005, 990, 931, 901, 862, 834, 794, 772, 733, 695 cmí1. HRMS (ESI): m/z calcd for C28H46O3Si 
[M + Na]+: 481.3114; found: 481.3136.  
 
(1R,3aR,4S,5R,7R,8S,8aR)-8-(benzyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-epoxyazulen-
5-ol (2) 
 
An oven-dried 5 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with ether B (20.0 mg, 44.0 ȝPRO.00 equiv) under an argon atmosphere. TBAF solution (1M 
in THF) (131 ȝL, 131 ȝPRO3.00 equiv) was added at 23 °C and the reaction was stirred at 50 °C for 
1 h. The solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (pentane±Et2O, 1:1) to give the alcohol 2 (14.5 mg, 42.1 ȝPRO97%) as a 
clear oil. 
>Į@D20 í26,6 (c 1.00, CHCl3), 1H NMR (400 MHz, CDCl3į 7.36 ± 7.21 (m, 5H), 4.70 (d, J = 11.0 Hz, 
1H), 4.58 (d, J = 11.0 Hz, 1H), 3.94 (td, J = 7.5, 2.5 Hz, 1H), 3.48 (d, J = 9.7 Hz, 1H), 2.54 (dd, J = 14.6, 
7.6 Hz, 1H), 2.40 (sept, J = 6.6 Hz, 1H), 2.09 (hept, J = 6.9 Hz, 1H), 1.95 (dddd, J = 13.8, 11.2, 8.0, 2.7 
Hz, 1H), 1.74 ± 1.61 (m, 3H), 1.47 ± 1.36 (m, 1H), 1.34 (d, J = 7.4 Hz, 1H), 1.31 ± 1.25 (m, 1H) 1.23 
(s, 3H), 1.11 ± 1.06 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.1 Hz, 3H) 
ppm. 13C NMR (126 MHz, CDCl3į 139.1, 128.4 (2C), 127.5, 127.3 (2C), 85.8, 85.0, 78.0, 76.9, 73.2, 
72.5, 47.5, 42.3, 32.5, 31.6, 31.3, 24.4, 19.4, 18.3, 17.6, 17.5 ppm, IR (neat): 3309, 2956, 2912, 
2870,1455, 1380, 1364, 1305, 1257, 1216, 1128, 1101, 1073, 1024, 977, 920, 877, 829, 795, 786, 752, 
697 cmí1. HRMS (ESI): m/z calcd for C22H32O3 [M + Na]+: 367.2249; found: 367.2263.  
(1R,3aR,4S,5R,7R,8S,8aR)-8-(benzyloxy)-7-isopropyl-1,4-dimethyl-5-(vinyloxy)decahydro-4,7-
epoxyazulene (3)  
 
An oven-dried 10 mL Schlenk tube equipped with a Teflon-coated magnetic stirring bar was charged 
with [IrCl(cod)]2 (3.90 mg, 5.81 ȝmol, 0.10 equiv) and Na2CO3 (36.9 mg, 348 ȝmol, 6.00 equiv) under 
an argon atmosphere. Dry PhMe (0.2 mL) was added followed by alcohol 2 (20.0 mg, 58.0 ȝmol, 1.00 
equiv) in dry PhMe (0.2 mL) and dry vinyl acetate (ȝ/, 1.16 mmol, 20.0 equiv). The reaction 
mixture was stirred for 16 h at 100 °C. The mixture was cooled down to 23 °C and was directly purified 
by flash chromatography on silica gel (pentane±Et2O, 30:1) to give the ether 3 (17.7 mg, 47.8 ȝPRO, 
82%) as a clear oil.  
[Į]D20 íc 0.88, CHCl3), 1H NMR (700 MHz, CDCl3) į 7.38 ± 7.27 (m, 4H), 7.32 ± 7.23 (m, 1H), 
6.35 (dd, J = 14.4, 6.8 Hz, 1H), 4.72 (d, J = 11.0 Hz, 1H), 4.60 (d, J = 11.0 Hz, 1H), 4.15 (dd, J = 14.4, 
1.8 Hz, 1H), 4.02 (dd, J = 7.5, 2.8 Hz, 1H), 3.99 (dd, J = 6.8, 1.8 Hz, 1H), 3.52 (d, J = 9.7 Hz, 1H), 2.45 
(dd, J = 14.3, 7.5 Hz, 1H), 2.46 ± 2.40 (m, 1H), 2.09 (hept, J = 6.9 Hz, 1H), 1.97 (dddd, J = 13.8, 11.4, 
8.0, 2.7 Hz, 1H), 1.74 (dd, J = 14.4, 2.7 Hz, 1H), 1.72 ± 1.63 (m, 2H), 1.42 (ddd, J = 13.1, 9.7, 6.4 Hz, 
1H), 1.32 ± 1.26 (m, 1H), 1.25 (s, 3H), 1.14 ± 1.06 (m, 1H), 1.04 (d, J = 7.0 Hz, 3H), 1.04 (d, J = 6.9 
Hz, 3H), 0.98 (d, J = 7.1 Hz, 3H) ppm; 13C NMR (176 MHz, CDCl3) į 150.6, 139.1, 128.5 (2C), 127.6, 
127.3 (2C), 87.6, 86.1, 84.7, 78.6, 78.0, 72.6, 48.2, 47.9, 39.4, 32.6, 31.9, 31.4, 24.5, 19.5, 18.4, 17.7, 
17.5 ppm; IR (neat): 2959, 2933, 2913, 2872, 1635, 1612, 1498, 1455, 1378, 1365, 1323, 1304, 1289, 
1260, 1198, 1176, 1109, 1067, 1015, 998, 964, 947, 917, 890, 812, 736 cmí1; HRMS (ESI): m/z calcd 
for C24H34O3 [M + Na]+: 393.2400; found: 393.2414. 
 
 
 
 
 
 
 2-(((1R,3aR,4S,5R,7R,8S,8aR)-8-(benzyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-
epoxyazulen-5-yl)oxy)ethan-1-ol (4)  
 
An oven-dried 5 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with vinyl ether 3 (PJȝPRO.00 equiv) and dry THF (1.4 mL) under an argon 
atmosphere. The solution was cooled to 0 °C and BH3ÂTHF (1M in THF) (P/ȝPRO
equiv) was slowly added at this temperature. The reaction was stirred for 2 h at 23 °C and then cooled 
down to 0 °C. NaOH (aq. 5 M, 0.70 mL) and H2O2 (30%, 1.40 mL) was added at 0 °C, the mixture was 
allowed to warm up to 23 °C and stirred for 2 h at 23 °C. The reaction mixture was diluted with dest. 
H2O (1.0 mL) and extracted with Et2O (4 × 2 mL). The combined organic phases were washed with sat. 
Na2S2O3 solution and dried over sodium sulfate. The solvent was removed under reduced pressure and 
the crude product purified by flash chromatography on silica gel (pentane±Et2O, 2:1) to give the alcohol 
4 (15.0 PJȝPRODVDFOHDURLO.  
>Į@D21 íc 0.49, CHCl3), 1H NMR (700 MHz, CDCl3į± 7.26 (m, 4H), 7.31 ± 7.22 (m, 1H), 
4.70 (d, J = 11.0 Hz, 1H), 4.59 (d, J = 11.0 Hz, 1H), 3.77 ± 3.65 (m, 2H), 3.59 (dd, J = 7.4, 2.8 Hz, 1H), 
3.55 (ddd, J = 9.4, 5.7, 3.6 Hz, 1H), 3.50 (d, J = 9.7 Hz, 1H), 3.39 (ddd, J = 9.5, 5.6, 3.7 Hz, 1H), 2.45 
± 2.36 (m, 1H), 2.37 (dd, J = 13.9, 7.4 Hz, 1H), 2.08 (hept, J = 6.9 Hz, 1H), 2.01 ± 1.89 (m, 2H), 1.72 
(dd, J = 13.9, 2.8 Hz, 1H), 1.73 ± 1.58 (m, 2H), 1.36 (ddd, J = 13.0, 9.7, 6.3 Hz, 1H), 1.30 ± 1.25 (m, 
1H), 1.24 (s, 3H), 1.09 ± 1.05 (m, 1H), 1.04 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 
7.1 Hz, 3H) ppm; 13C NMR (176 MHz, CDCl3į (2C), 127.5, 127.3 (2C), 86.0, 85.0, 80.7, 
78.0, 72.5, 70.1, 62.1, 48.2, 47.8, 39.2, 32.6, 32.4, 31.4, 24.5, 19.3, 18.5, 17.8, 17.5 ppm; IR (neat): 
3447, 2957, 2932, 2873, 1455, 1379, 1304, 1260, 1212, 1156, 1109, 1066, 1022, 990, 925, 891, 749, 
737 cmí1; HRMS (ESI): m/z calcd for C24H36O4 [M + Na]+: 411.2506; found: 411.2518. 
 
 
 
 
 
(2-(((1R,3aR,4S,5R,7R,8S,8aR)-8-(benzyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-
epoxyazulen-5-yl)oxy)ethoxy)(tert-butyl)dimethylsilane (5)  
 
An oven-dried 5 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with alcohol 4 (15.0 mg, 38.6 ȝPRO.00 equiv) and dry CH2Cl2 (0.60 mL) under an argon 
atmosphere. TBSCl (11.6 mg, 77.2 ȝPRO2.00 equiv), imidazole (8.70 mg, 127 ȝPRO3.30 equiv) and 
DMAP (0.70 mg, 6.00 ȝPRO0.15 equiv) were added at 23 °C and the mixture was stirred for 20 h at 
this temperature. The reaction was quenched with sat. NaHCO3 solution (5 mL) and extracted with 
CH2Cl2 (3 × 10 mL). The combined organic phases were dried over sodium sulfate and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography on silica gel 
(pentane±Et2O, 25:1) to give the silyl ether 5 (15.0 mg, 29.8 ȝPRO77%) as a clear oil. 
[Į]D20 íc 1.00, CHCl3), 1H NMR (700 MHz, CDCl3) į 7.34 ± 7.30 (m, 4H), 7.28 ± 7.25 (m, 1H), 
4.70 (d, J = 11.1 Hz, 1H), 4.59 (d, J = 11.1 Hz, 1H), 3.76 ± 3.70 (m, 2H), 3.59 (dd, J = 7.5, 2.9 Hz, 1H), 
3.51 ± 3.46 (m, 2H), 3.40 ± 3.35 (m, 1H), 2.42 ± 2.37 (m, 1H), 2.35 (dd, J = 13.9, 7.5 Hz, 1H), 2.07 
(hept, J = 6.8 Hz, 1H), 1.94 (dddd, J = 14.0, 11.4, 8.0, 2.6 Hz, 1H), 1.73 (dd, J = 13.8, 2.8 Hz, 1H), 1.69 
± 1.59 (m, 2H), 1.36 (ddd, J = 13.0, 9.7, 6.3 Hz, 1H), 1.30 ± 1.24 (m, 1H), 1.23 (s, 3H), 1.10 ± 1.05 (m, 
1H), 1.04 (t, J = 6.7 Hz, 6H), 0.96 (d, J = 7.1 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H) ppm; 
13C NMR (176 MHz, CDCl3) į 139.3, 128.4 (2C), 127.5, 127.3 (2C), 85.9, 85.1, 80.7, 78.2, 72.5, 70.9, 
63.0, 48.1, 47.9, 39.3, 32.6, 32.3, 31.4, 26.1 (3C), 24.4, 19.4, 18.5, 18.5, 17.9, 17.5, -5.1, -5.1 ppm; IR 
(neat): 2955, 2929, 2870, 1471, 1462, 1380, 1363, 1302, 1255, 1214, 1134, 1100, 1067, 1021, 991, 954, 
835, 811, 777, 750, 735 cmí1; HRMS (ESI): m/z calcd for C30H50O4Si [M + Na]+: 525.3370; found: 
525.3389. 
 
 
 
 
 
 
(1R,3aR,4S,5R,7R,8S,8aR)-5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-7-isopropyl-1,4-
dimethyldecahydro-4,7-epoxyazulen-8-ol (6)  
 
An oven-dried 5 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with silyl ether 5 (15.0 mg, 29.8 ȝPRO.00 equiv) and MeOH (1.0 mL). Pd/C (dry, 20 wt%) 
(4.20 mg, 6.00 ȝmol, 0.20 equiv) was added and the reaction atmosphere was saturated with hydrogen 
by three times evacuating and setting under H2 atmosphere. The reaction was stirred 5 h at 23 °C under 
an H2 atmosphere (1 bar). The suspension was filtered over kieselgur and the product was eluted with 
MeOH (20 mL). The solvent was removed under reduced pressure and the crude product purified by 
flash chromatography on silica gel (pentane±Et2O, 3:1) to give the alcohol 6 (9.00 mg, 21.8 mmol, 73%) 
as a clear oil. 
>Į@D21 íc 1.00, CHCl3), 1H NMR (700 MHz, CDCl3į± 3.72 (m, 2H), 3.64 (d, J = 10.2 Hz, 
1H), 3.59 (dd, J = 7.4, 2.8 Hz, 1H), 3.53 ± 3.49 (m, 1H), 3.41 (dt, J = 10.3, 5.3 Hz, 1H), 2.35 ± 2.28 (m, 
1H), 2.27 (dd, J = 13.8, 7.4 Hz, 1H), 2.02 ± 1.96 (m, 2H), 1.71 (dd, J = 14.1, 2.6 Hz, 1H), 1.71 ± 1.67 
(m, 1H), 1.59 ± 1.54 (m, 1H), 1.24 (s, 3H), 1.23 ± 1.18 (m, 2H), 1.13 ± 1.08 (m, 1H), 1.07 (d, J = 6.8 
Hz, 3H), 1.07 (d, J = 7.1 Hz, 3H), 0.91 (s, 9H), 0.90 (d, J = 7.2 Hz, 3H), 0.09 (s, 3H), 0.09 (s, 3H) ppm; 
13C NMR (176 MHz, CDCl3į 
(3C), 25.9, 19.3, 18.6, 18.5, 17.7, 17.1, -5.1, -5.1 ppm; IR (neat): 3439, 2954, 2930, 2867, 1471, 1463, 
1383, 1363, 1300, 1255, 1215, 1136, 1101, 1043, 1021, 1003, 953, 923, 903, 888, 835, 812, 777, 
734 cmí1; HRMS (ESI): m/z calcd for C23H44O4Si [M + Na]+: 435.2901; found: 435.2910. 
 
 
 
 
 
 
 
 
(1R,3aR,4S,5R,7R,8S,8aR)-5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-7-isopropyl-1,4-
dimethyldecahydro-4,7-epoxyazulen-8-yl cinnamate (7)  
 
An oven-dried 5 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with cinnamic acid (PJȝPRO.00 equiv) and dry PhMe (0.27 mL) under an argon 
atmosphere. Et3N ( ȝ/ 327 ȝPRO  equiv) and 2,4,6-trichlorbenzoylchloride  ȝ/ 137 
ȝmol, 4.20 equiv) were added at 23 °C. The reaction mixture was stirred for 1 h at 23 °C. DMAP (18.4 
mg, 150 ȝmol, 4.60 equiv) and alcohol 6 (13.5 mg, 32.7 ȝmol, 1.00 equiv) were added to the reaction, 
the flask was sealed and stirred for 14 h at 80 °C. The reaction was quenched by adding sat. NaHCO3 
solution (3 mL) and the mixture was extracted with Et2O (2 × 20 mL). The organic phase was dried over 
sodium sulfate and the solvent was removed under reduced pressure. The crude product was purified by 
flash chromatography on silica gel (pentane±Et2O, 12:1) to give the ester 7 PJȝPRO
as a clear oil. 
>Į@D20 íc 1.00, CHCl3), 1H NMR (700 MHz, CDCl3įGJ = 16.0 Hz, 1H), 7.54 ± 7.51 (m, 
2H), 7.41 ± 7.37 (m, 3H), 6.39 (d, J = 16.0 Hz, 1H), 5.10 (d, J = 10.3 Hz, 1H), 3.79 ± 3.73 (m, 2H), 3.69 
(dd, J = 7.5, 3.0 Hz, 1H), 3.55 ± 3.51 (m, 1H), 3.48 ± 3.38 (m, 1H), 2.46 (dd, J = 13.8, 7.4 Hz, 1H), 2.13 
± 2.07 (m, 1H), 1.94 ± 1.85 (m, 2H), 1.81 (dd, J = 13.7, 2.8 Hz, 1H), 1.76 ± 1.68 (m, 2H), 1.44 (ddd, J 
= 13.2, 10.3, 6.5 Hz, 1H), 1.26 (s, 3H), 1.25 ± 1.21 (m, 1H), 1.12 (dd, J = 11.3, 7.3 Hz, 1H), 1.02 (d, J 
= 6.8 Hz, 3H), 0.96 (d, J = 7.1 Hz, 3H), 0.94 (d, J = 7.1 Hz, 3H), 0.91 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H) 
ppm; 13C NMR (176 MHz, CDCl3į (2C), 128.2 (2C), 118.4, 85.4, 
85.3, 80.8, 71.9, 71.1, 63.0, 47.8, 47.0, 40.2, 33.5, 31.3, 31.2, 26.1 (3C), 25.0, 19.3, 18.5 (2C), 17.8, 
17.1, -5.1, -5.1 ppm; IR (neat): 2954, 2930, 2882, 2857, 1713, 1637, 1471, 1463, 1450, 1384, 1368, 
1333, 1302, 1280, 1254, 1202, 1170, 1138, 1100, 1042, 1014, 979, 955, 926, 835, 812, 777, 767, 709 
cmí1; HRMS (ESI): m/z calcd for C32H50O5Si [M + Na]+: 565.3320; found: 565.3339. 
 
 
 
(1R,3aR,4S,5R,7R,8S,8aR)-5-(2-hydroxyethoxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-
epoxyazulen-8-yl cinnamate (1)  
 
An oven-dried 5 mL round-bottom-flask equipped with a Teflon-coated magnetic stirring bar was 
charged with ester 7 (13.6 mg, 25.1 ȝPRO .00 equiv) and dry THF (0.10 mL) under an argon 
atmosphere. TBAF solution (1M in THF) (62.6 ȝL, 62.6 ȝPRO2.50 equiv) was added at 0 °C. The 
reaction was allowed to warm up to 23 °C and stirred for 4 h at this temperature. After this time dest. 
H2O was added to quench the reaction. The aqueous phase was extracted with Et2O (3 × 20 mL). The 
combined organic phases were dried over sodium sulfate and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (pentane±Et2O, 1:1) to 
give the alcohol 1 (10.6 mg, 24.7 ȝPRO99%) as a clear oil. 
>Į@D20 íc 1.00, CHCl3), 1H NMR (700 MHz, CDCl3įGJ = 16.0 Hz, 1H), 7.52 (ddd, J = 5.9, 
2.9, 1.9 Hz, 2H), 7.42 ± 7.35 (m, 3H), 6.39 (d, J = 16.0 Hz, 1H), 5.12 (d, J = 10.3 Hz, 1H), 3.80 ± 3.68 
(m, 2H), 3.68 (dd, J = 7.4, 2.9 Hz, 1H), 3.60 (ddd, J = 9.4, 5.8, 3.5 Hz, 1H), 3.45 (ddd, J = 9.4, 5.6, 3.6 
Hz, 1H), 2.49 (dd, J = 13.8, 7.4 Hz, 1H), 2.17 ± 2.05 (m, 1H), 1.97 ± 1.84 (m, 2H), 1.79 (dd, J = 13.9, 
2.7 Hz, 1H), 1.77 ± 1.70 (m, 2H), 1.44 (ddd, J = 13.2, 10.3, 6.5 Hz, 1H), 1.27 (s, 3H), 1.26 ± 1.22 (m, 
1H), 1.11 (dd, J = 11.3, 7.3 Hz, 1H), 1.02 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 7.1 Hz, 3H), 0.94 (d, J = 7.1 
Hz, 3H) ppm; 13C NMR (176 MHz, CDCl3į (2C), 128.2 (2C), 118.3, 
85.4, 85.4, 80.7, 71.7, 70.4, 62.1, 47.7, 47.0, 40.2, 33.6, 31.3, 31.2, 25.0, 19.2, 18.5, 17.7, 17.1 ppm; IR 
(neat): 3453, 2956, 2933, 2872, 1710, 1636, 1496, 1449, 1368, 1334, 1303, 1268, 1202, 1170, 1138, 
1107, 1072, 1043, 1014, 981, 956, 926, 891, 815, 798, 767, 738, 723, 710, 686, 659 cmí1; HRMS (ESI): 
m/z calcd for C26H36O5 [M + H]+: 429.2636; found: 429.2635. 
 
 
 
  
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
